Master Tuberoinfundibular Pathway (Dopaminergic) with Picmonic for Medicine

The tuberoinfundibular pathway begins in the arcuate (infundibular) nucleus of the hypothalamus.

The tuberoinfundibular pathway ends at the median eminence of the hypothalamus.

Within the tuberoinfundibular pathway, the release of dopamine naturally inhibits the secretion of prolactin from the anterior pituitary gland.

The use of antipsychotics contributes to a dopamine blockade. Therefore, with dopamine blocked, prolactin levels can increase and contribute to hyperprolactinemia.

If there is a defect or the inhibition of the tuberoinfundibular pathway, this inhibits the release of dopamine. With dopamine inhibited, this leads to increased levels of prolactin.

Defects of the tuberoinfundibular pathway will lead to decreased dopamine and increased levels of prolactin. Hyperprolactinemia can lead to conditions such as sexual dysfunction, decreased libido, gynecomastia, and galactorrhea.

Defects of the tuberoinfundibular pathway will lead to decreased dopamine and increased levels of prolactin. Hyperprolactinemia can lead to conditions such as sexual dysfunction, decreased libido, gynecomastia, and galactorrhea.

Defects of the tuberoinfundibular pathway will lead to decreased dopamine and increased levels of prolactin. Hyperprolactinemia can lead to conditions such as sexual dysfunction, decreased libido, gynecomastia, and galactorrhea.